EGFR and glioblastoma: In recent years, some molecular markers and biological risk factors, such as MGMT (O6‐methylguanine DNA methyltransferase),10 IDH (isocitrate dehydrogenase),11 EGFR (epidermal growth factor receptor),12 PTEN (phosphatase and tensin homologue)13 and 1p/19q co‐deficiency14 have been discovered to be valuable for individualized therapeutic approaches and targeted therapies against GBM.